JP4748868B2 - Dementia diagnosis device - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a dementia diagnosis apparatus for determining whether a dementia patient has Alzheimer-type dementia or cerebrovascular dementia.
[0002]
[Prior art]
It is said that there are about 1 million patients with dementia in Japan alone.
This dementia can be subdivided into cortical dementia such as Alzheimer-type dementia and Pick's disease, subcortical dementia such as Parkinson's disease and Huntington's chorea, and cerebrovascular dementia. Cerebrovascular dementia and Alzheimer's dementia, each accounting for about 50%.
[0003]
At present, there are many types of therapeutic agents for cerebrovascular dementia and their therapeutic effects have been recognized. However, acetylcholinesterase inhibitors have recently been developed as therapeutic agents for Alzheimer type dementia.
Although this therapeutic agent is not a fundamental therapeutic agent, it can delay the progression of the disease, so that if it is administered early, a sufficient therapeutic effect can be obtained.
Therefore, it is effective to discriminate Alzheimer-type dementia or cerebrovascular dementia in the early stage of dementia and perform early treatment.
[0004]
By the way, as a diagnosis of Alzheimer-type dementia, examinations by the Hasegawa scale (HDS) and MMSE (Mini Mental State Examination) are known, and the score of an answer to a preset question is a predetermined cut-off point ( If the Hasegawa method is 20 points) or less, it is diagnosed as Alzheimer-type dementia.
However, in the early stage of Alzheimer-type dementia, a score higher than the cut-off point may be obtained based on the results of the interview, and if it is diagnosed as Alzheimer-type dementia at this point, the efficacy of the acetylcholinesterase inhibitor is remarkable. Despite the fact, it is often diagnosed as normal.
[0005]
Therefore, recently, a mydriatic diluent that causes an enlarged pupil response when instilled in patients with early stage Alzheimer-type dementia has been developed. A method for diagnosing whether or not Alzheimer's dementia is measured by measuring (area) and determining the enlargement ratio after instillation has been published (US SCIENSE VOL.266, 11NOVEMBER 1994).
[0006]
The method is, for example, instilling a mydriatic diluted solution into the left eye, and then measuring the pupil size, for example, a change in diameter, for 30 to 60 minutes with a ruler. It is determined whether or not the patient has Alzheimer's dementia based on the size of the above.
[0007]
[Problems to be solved by the invention]
However, the size of the pupil changes not only due to the effect of the mydriatic agent, but also due to ambient brightness and other factors. Therefore, the pupil image on the non-eye-dropper side (right eye) is usually captured at the same time. This is troublesome in that it is necessary to always refer to the size of the pupil on the non-instillation side when measuring the length and determining whether the pupil on the instillation side has become large or not.
[0008]
For this reason, it is difficult to quantitatively measure changes in the size of the pupil on the ophthalmic side caused by the mydriatic alone, and it is difficult to determine whether or not it is Alzheimer-type dementia, which may lead to misdiagnosis. There was a problem that there was.
Further, since the pupil diameter is measured with a ruler, not only a time lag occurs when measuring the size of the left and right pupils, but also the measurement accuracy is low.
[0009]
Furthermore, if an early diagnosis of Alzheimer-type dementia is made, an anti-dementia drug such as an acetylcholinesterase inhibitor is administered to delay the progression, but whether the therapeutic drug is really effective for the patient However, it was difficult to determine quantitatively, and there was a problem that it was difficult to determine an appropriate dose.
[0010]
Therefore, the present invention can easily and accurately determine whether or not it is Alzheimer-type dementia by quantitatively measuring the change in the size of the pupil on the ophthalmic side caused by only the mydriatic agent. To make it possible to perform appropriate treatment by quantitatively grasping the effects of Alzheimer's treatment for dementia, confirming the therapeutic effect, and making a definitive diagnosis This is the second issue.
[0011]
[Means for Solving the Problems]
In order to solve this problem, the invention of claim 1 is a dementia diagnosis apparatus for obtaining basic data for determining whether a dementia patient is Alzheimer-type dementia or cerebrovascular dementia, based on the image of the pupil imaging device for an image shot with a constant illuminance ophthalmic side of the pupil when the eye Alzheimer diagnostic mydriatic dilutions eye, given the size of the pupil in a given measurement time While measuring at time intervals, normalizing the size of the measured pupil with the size of the non-eye-dropped pupil taken simultaneously, and the normalized pupil size change as mydriatic data And a display device for displaying.
[0012]
According to the first aspect of the present invention, since the illuminance that most influences the change in the size of the pupil is made constant and the size of the pupil is imaged, the change in the size of the pupil due to the change in the illuminance in the surroundings is detected. By removing it, it is possible to measure the change in pupil size caused solely by the mydriatic diluent.
In addition, since the size of the pupil is measured from the captured image, numerical values specifying the size such as the diameter and area of the pupil can be calculated extremely accurately.
[0013]
Also, since normalized by the size of the pupil size simultaneously measured non eye side of the point eye side of the pupil, to remove the change in the size of the pupil due to factors other than the illuminance, mydriatic A change in the size of the pupil due to only the diluent can be measured more accurately.
Therefore, even if the temporal change of the pupil size on the eye drops side is small, if the normalized pupil size increases with time, the pupil is enlarged by the mydriatic agent, so the Alzheimer type It can be diagnosed as dementia.
In addition, even if the temporal change in the size of the pupil on the eyedrop side is large, if the normalized data does not change so much, the pupil enlargement on the eyedrop side is caused by other factors, Since the pupil is not enlarged by the agent, it can be diagnosed as not having Alzheimer-type dementia.
[0014]
In this case, if the size of the pupil is expressed as a ratio to the size of the pupil before or just after the instillation, the size of the pupil in the initial state can be calculated by calculating the ratio to the size of the pupil before or after the instillation. Since the pupil size measured after instillation directly represents the enlargement ratio, the comparison becomes extremely easy.
[0015]
In addition, the pupil image is imaged for 60 minutes at intervals of 5 minutes, for example, and in order to improve examination efficiency, when trying to image five patients every minute, which pupil image is the pupil image of which patient. May become unknown.
Therefore, as in the seventh aspect of the invention, an iris pattern is stored when a pupil image is captured by the pupil imaging device, and the iris pattern is stored in advance each time a pupil image is input. If the iris pattern identification means for matching is provided, the pupil image of the same patient can be found immediately even if the patient name is forgotten to be recorded.
[0016]
Furthermore, if the pupil imaging device and the arithmetic processing device are equipped with a transmitter and a receiver that wirelessly transmit and receive the captured pupil image, there is no connection cord for connecting the two, so there is no troublesome wiring. No connection mistakes will occur.
[0017]
The invention of claim 2 includes an inquiry result input device for inputting a result based on an answer to each question of a diagnostic test for diagnosis of dementia set in advance, and an arithmetic device for summing up the score corresponding to the result of each question. characterized in that e Bei interview test execution means with.
[0018]
According to the second aspect of the present invention, first, when an answer to each question of the Hasegawa formula scale (HDS) or MMSE is input by the inquiry test execution means, a total score for the answer is calculated, and this score is determined as a predetermined cut. If it is lower than the off-point (20 points on the Hasegawa scale), it is diagnosed as Alzheimer-type dementia.
However, if the score is higher than the cut-off point, the possibility of early Alzheimer-type dementia or the possibility of cerebrovascular dementia remains, so a mydriatic test was performed, and as a result, the pupil enlarged. For example, even if it is higher than the cut-off point, it can be diagnosed as Alzheimer-type dementia, and when the pupil does not expand, it can be diagnosed that the suspicion of cerebrovascular dementia is extremely high.
[0019]
The invention according to claim 6 is a dementia diagnosis device for monitoring the therapeutic effect of a therapeutic agent for Alzheimer-type dementia, wherein the pupil on the eyedrop side when the dilated solution for Alzheimer diagnosis is instilled into one eye is fixed. based on the image of the pupil imaging device for an image shot with illuminance of the pupil size while measuring at predetermined time intervals in a predetermined measurement time, the measured pupil size simultaneously imaged non instillation side Mydriatic test execution means that normalizes the pupil size and memorizes the change in the normalized pupil size as mydriatic data, and on the left and right pupils before and after administration of Alzheimer's treatment for dementia And a display device for displaying each mydriatic data measured by the mydriatic test execution means by instilling a mydriatic diluent.
[0020]
According to the invention of claim 6 , each mydriatic data measured by instilling a mydriatic diluent on the left and right pupils can be displayed before and after administration of the Alzheimer-type dementia therapeutic agent. If the enlargement rate is small before and after administration, it can be determined that the therapeutic agent is effective.
[0021]

DETAILED DESCRIPTION OF THE INVENTION

Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.
FIG. 1 is an overall configuration diagram showing an example of a dementia diagnosing apparatus according to the present invention, FIG. 2 is a flowchart showing a processing procedure of the apparatus of the present invention, FIG. 3 is a chart showing question contents of a Hasegawa scale, FIGS. Is a graph showing the measurement results.
[0022]
The dementia diagnosis device 1 of this example obtains basic data for determining whether a dementia patient has Alzheimer type dementia or cerebrovascular dementia, and confirms the therapeutic effect of a therapeutic agent for Alzheimer type dementia Is to do.
[0023]
The dementia diagnosis device 1 includes an input device such as a keyboard 6a and a mouse 6b in an input / output port 5 of a computer main body 4 provided with an arithmetic device 2 that performs data processing according to a predetermined program and a storage device 3 that stores data and programs. 6, a display device (display device) 7 that displays a calculation result of the calculation device 2 and an input character of the input device 6, and a printer (display device) 8 that prints an image displayed on the display device 7 are connected. ing.
[0024]
The input / output port 5 is connected to a receiver 9 that receives an image signal transmitted wirelessly, and is transmitted from a transmitter 11 provided in a pupil imaging device 10 that simultaneously images the left and right pupils. The pupil image is received and input to the arithmetic unit 2.
[0025]
The pupil image capturing apparatus 10 individually captures the respective pupils facing the left and right pupil positions, for example, in a goggle-type mask that can be worn on the face or a binocular lens barrel that is configured to look into with both eyes. The two imaging cameras 12L and 12R, the illuminance adjusting LED illumination 13, the illuminance sensor 14, and the imaging infrared LED illumination 15 are arranged.
The illuminance adjusting LED illumination 13 and the illuminance sensor 14 are connected to an illuminance controller 16 so as to prevent a measurement error by maintaining a constant illuminance condition during pupil photographing.
It should be noted that at least one LED illumination 13 for adjusting the illuminance may be disposed so as to oppose the upper and lower positions or the left and right positions of the eyeball, and the irradiation direction is the irradiation direction even when the irradiation light is directly irradiated to the eyeball. The direction may be such that the light is indirectly reflected so that the light is once reflected in the imaging device 10 and then incident on the eyeball.
Moreover, as LED used for the LED illumination 13 for illumination intensity adjustment, although visible light color is desirable, infrared light may be sufficient and the luminescent color is not ask | required.
[0026]
FIG. 2 shows a data processing procedure by the dementia diagnostic apparatus 1.
When the diagnostic apparatus 1 is started up, an inquiry test execution means (steps STP1 to STP3) is started. First, in step STP1, the question contents and answers of a preset diagnostic test for dementia diagnosis such as the Hasegawa scale (HDS), etc. Since the entry column is displayed, the doctor sequentially asks questions based on this, and inputs the answers sequentially with the keyboard 6a and the mouse 6b.
[0027]
When all questions have been completed and the answers have been entered and the confirmation key (for example, the Eenter key) is hit, the process proceeds to step STP2, and the answer to each question is dealt with by referring to the preset score table 13 The total score to be calculated is calculated.
Next, the process proceeds to step STP3, and each answer, the total score, and a code (name and ID code) for identifying the patient are recorded in a folder Fn created in advance in a predetermined storage area of the storage device 3.
[0028]
On the Hasegawa scale, 20 points are cut-off points. If the score is 20 points or less, it is diagnosed as Alzheimer-type dementia. If the total score is 21 to 26 points, dementia is suspected, and 27 points or more are normal. It is judged.
Therefore, in step STP4, it is determined whether the total score is 20 points or less, 21 to 26 points, or 27 points or more. If the total score is 20 points or less and 27 points or more, in step STP5, Alzheimer type dementia and Whether it is normal is displayed and the process is terminated.
In the case of 21 to 26 points, the process proceeds to the mydriatic test execution means of steps STP6 to 15 to determine whether it is an early stage Alzheimer type dementia or cerebrovascular dementia.
[0029]
When the process proceeds to the mydriatic test execution means (steps STP6 to STP15), the left and right pupils are simultaneously imaged at predetermined time intervals before taking in the Alzheimer diagnostic mydriatic solution for one eye or immediately after the instillation, and a pupil image is captured. .
First, in step STP6, the pupil imaging device 10 simultaneously captures the left and right pupils to capture the pupil image, and simultaneously recognizes the iris pattern based on the image, and then proceeds to step STP7.
[0030]
In step STP7, the iris pattern stored in each folder Fn is collated in advance. If they match, the process proceeds to step STP8 and the image data of the pupil image is stored in the folder Fn in which the matched iris pattern is recorded. Is stored, and if they do not match, the process proceeds to step STP9 and is stored in the folder Fn for the patient created in advance.
As a result, the patient who has already taken the pupil image is automatically stored in the folder Fn of the same patient without assigning the patient name, so that the trouble of managing the pupil image is remarkably reduced. The
[0031]
Next, in step STP10, it is determined that the processes in steps STP6 to STP9 are repeated a predetermined number of times (for example, 13 times when imaging a 60-minute pupil change every 5 minutes) within a predetermined measurement time. Then, the process proceeds to step STP11.
In addition, when imaging every 5 minutes, even if another person's pupil is imaged during that time, the pupil image is automatically stored in the folder Fn of each patient. It doesn't become unknown.
[0032]
In step STP11, the size of the pupil at each measurement time is calculated. Specifically, when an area is used as the size of the pupil, for example, it is calculated by a ratio (mydriatic ratio) when the area of the left and right pupils before or after instillation is 100%.
[0033]
Next, in step STP12, the mydriatic ratio on the instillation side of the mydriatic solution for Alzheimer diagnosis is divided by the simultaneously measured mydriatic ratio on the non-instillation side, and the change is stored as mydriatic data.
[0034]
In step STP13, changes in the left and right mydriatic ratios and mydriatic data are displayed on the display device 7, and the graph image is stored in the same folder Fn, and is output by the printer 8 as necessary.
[0035]
In this example, generally, when the pupil area exceeds 127% (113% in diameter) by the mydriatic test, the suspicion of Alzheimer-type dementia is extremely high, and as shown in FIGS. When displaying pupil data in a graph, it is desirable to attach a determination reference line M that is 127% of the pupil area.
[0036]
Next, in step STP14, the average value is calculated based on the mydriatic data, and in step STP15, the score of the interrogation test for dementia diagnosis as shown in FIG. 6 is set as the X coordinate, and the average value of the mydriatic data is set as the Y coordinate. A graph in which the points to be plotted are plotted is displayed on the display device 7, and the graph image is stored in the folder Fn. If necessary, this is output by the printer 8, and the processing is terminated.
[0037]
In this case, if the graph is displayed with the orthogonal reference lines CP and AH indicating the cut-off point of the diagnostic test for dementia diagnosis and the size of the pupil serving as the criterion for Alzheimer-type dementia, the region on the left side of the reference line CP Alzheimer-type dementia when plotted in R ₁ and the region R ₂ above the reference line AH, and cerebrovascular dementia when plotted in the region R ₃ to the right of the reference line CP and below the reference line AH It is judged that.
[0038]
When the Hasegawa scale (HDS) score is used for the X coordinate, the reference line CP is 20 points, and when the average value of mydriatic data is used as the Y coordinate, the reference line AH is 125 to 135% (pupil area) 112-116% in diameter), optimally 129-130% in pupil area (114% in pupil diameter).
[0039]
The mydriatic data is normalized by dividing the mydriatic ratio on the instillation side by the mydriatic ratio on the non-instillation side based on the mydriatic ratio when the area of the pupil immediately before instillation or immediately after the instillation is 100%. However, the present invention is not limited to this, and a numerical value that specifies the size of the pupil, such as the mydriatic ratio on the eye drop side, can be selected.
[0040]
In this case, the Y axis represents a change in the size of the pupil, such as the maximum value of the normalized mydriatic ratio, the average value of the mydriatic ratio on the eye drop side, and the maximum value of the mydriatic ratio on the eye drop side. Any numerical value can be used.
When the maximum value of the mydriatic ratio normalized as the Y coordinate is used, the reference line AH is 155 to 165% in pupil area (125 to 128% in pupil diameter), and optimally, 159 to pupil area. It was 160% (126% in pupil diameter).
When the average value of the mydriatic ratio on the eyedrop side is used as the Y coordinate, the reference line AH is 115 to 120% in pupil area (107 to 109% in pupil diameter), and optimally 117 to 118 in pupil area. % (108% in pupil diameter).
Further, when the maximum value of the mydriatic ratio on the eyedrop side is used as the Y coordinate, the reference line AH is 145 to 155% in pupil area (120 to 125% in pupil diameter), and optimally 150% in pupil area ( The pupil diameter was 122%).
[0041]
In this way, when using mydriatic data or the average value and maximum value of mydriatic ratio as the Y coordinate, the measurement time is required to be at least 20 minutes or more and plotted on the graph based on the data when censored in less than 20 minutes. However, Alzheimer-type dementia and cerebrovascular dementia could not be accurately distinguished, but when measured at 40 minutes, 50 minutes, 60 minutes, and at least 40 minutes, the result is longer than that. There was no change.
[0042]
Moreover, if the dementia diagnosis apparatus 1 is used, the therapeutic effect of the Alzheimer type dementia therapeutic agent can also be monitored.
In this case, the treatment should be stored as mydriatic data stored by performing the processing of steps STP6 to STP 13 before administration of the Alzheimer-type dementia treatment drug, and the drug efficacy should be confirmed after the start of treatment drug treatment. Is confirmed, the processes of steps STP6 to STP15 are performed again to store mydriatic data, and both are displayed on the same graph or on individual graphs as shown in FIG. This is done by comparing them.
[0043]
In this case, when imaging a pupil image after the start of administration of a therapeutic agent, for example, after one month has elapsed, since the pupil image has already been captured by the iris pattern, the iris pattern of the image is collated and automatically Since it is stored in the folder Fn of the same patient, it is not necessary to add a patient name to the image data and manage the pupil image.
[0044]
4 to 7 are graphs obtained by the dementia diagnostic apparatus 1. FIG.
4 and 5 show that the patient's left eye of the Hasegawa scale has a total score of 21 to 26, a mydriatic solution is instilled into the left eye, saline is instilled into the right eye, and every 5 minutes immediately after instillation. Shows the results of a mydriatic test in which the pupil is imaged a total of 13 times for 60 minutes. The mydriatic ratio (mydriatic data) is shown.
[0045]
According to the result of FIG. 4, mydriatic data has reached 130% after 25 minutes, and since there is a tendency to increase without decreasing thereafter, when such data is obtained, the Alzheimer type It can be diagnosed that suspicion of dementia is high.
[0046]
In addition, according to the results of FIG. 5, mydriatic data has remained around 100% without reaching 127%. When such data is obtained, the suspected Alzheimer-type dementia is It is low, and it can be diagnosed that suspicion of cerebrovascular dementia is extremely high.
[0047]
FIG. 6 shows the average value of mydriatic data measured on the basis of pupil images taken every 5 minutes within a measurement time of 40 minutes, with the Hasegawa scale (HDS) score as the X coordinate for many patients. The graph which plotted the point made into Y coordinate is shown.
Patients with Alzheimer-type dementia displayed as squares with reference to the cut-off point of the diagnostic test for dementia diagnosis and the baselines CP and AH that represent the size of the pupil as the criteria for determining Alzheimer-type dementia A patient with cerebrovascular dementia plotted in the left region R ₁ or the region R ₂ above the reference line AH and displayed in a circle is in the region R ₃ on the right side of the reference line CP and below the reference line AH. Plotted.
From this, when plotted in the region R ₁ or R ₂ , it can be diagnosed as Alzheimer type dementia, and when plotted in the region R ₃ , it can be diagnosed as cerebrovascular dementia. .
[0048]
Further, FIG. 7 shows mydriatic data on the same graph for Alzheimer-type dementia patients prescribed with an anti-dementia drug such as an acetylcholinesterase inhibitor on the same graph before and 1 month after the administration. is there.
According to this graph, in comparison to mydriasis data D ₁ of the pre-dose illustrated by broken lines, since a small pupillary mydriasis data D ₂ when 1 month has passed after administration illustrated by the solid line, the therapeutic agent is You can see that it works.
By describing them on the same graph in this way, the comparison is facilitated and the therapeutic effect of the therapeutic agent can be objectively known.
[0049]
In the description of the embodiment, the case where the left and right eyes are simultaneously imaged by the pupil imaging device 10 and the size of the pupil is calculated based on the respective pupil images has been described, but the present invention is not limited thereto. Instead, the size of the pupil may be calculated by imaging only the pupil on the eye drop side.
As a mydriatic, tropicamide having a concentration of 0.01%, 0.0075%, 0.0050%, and 0.0025% can be used. Alternatively, pilocarbine hydrochloride can be used. Good.
Furthermore, when imaging the pupil with the imaging device 10, it is desirable to maintain the illuminance near the eyeball at about 110 lux, 130 lux, and 150 lux.
[0050]
【The invention's effect】
As described above, according to the present invention, the size of the pupil on the ophthalmic side is normalized by the size of the pupil on the non-ophthalmic side that has been miscellaneous, so that the ophthalmic side caused by the mydriatic only Anyone can quantitatively measure the change in the size of the pupil, and there is an excellent effect that it is possible to easily and accurately determine whether or not it is Alzheimer's dementia.
In addition, it is possible to easily determine whether the therapeutic effect of the therapeutic agent has appeared by performing a mydriatic test before and after administration of the Alzheimer-type dementia therapeutic agent and comparing the pupil area. There is also an effect that it can be used as reference data for determining the amount.
[Brief description of the drawings]
FIG. 1 is an overall configuration diagram showing an example of a dementia diagnosis apparatus according to the present invention.
FIG. 2 is a flowchart showing a processing procedure of the apparatus of the present invention.
FIG. 3 is a chart showing the contents of a question on the Hasegawa scale.
FIG. 4 is a graph showing measurement results.
FIG. 5 is a graph showing measurement results.
FIG. 6 is a graph showing measurement results.
FIG. 7 is a graph showing measurement results.
[Explanation of symbols]
DESCRIPTION OF SYMBOLS 1 ......... Dementia diagnosing device 2 ......... Calculation device 3 ......... Storage device 4 ......... Computer body 5 ......... Input / output port 6 ......... Input device 7 ......... Display device (display device)
8: Printer (display device)
9... Receiver 10... Pupil imaging device 11... Transmitter 12 R, 12 L.

Claims (7)

A dementia diagnostic apparatus for obtaining basic data for determining whether a dementia patient is Alzheimer-type dementia or cerebrovascular dementia,
Based on the image of the pupil imaging device (10) that images the pupil on the eye drop side with a constant illuminance when the Alzheimer diagnostic mydriatic diluent is applied to one eye, the size of the pupil is determined within a predetermined measurement time. And an arithmetic unit (2) that normalizes the measured pupil size with the size of the pupil on the non-instilled side simultaneously imaged, and a change in the normalized pupil size And a display device (7) for displaying as mydriatic data. A dementia diagnostic apparatus for obtaining basic data for determining whether a dementia patient is Alzheimer-type dementia or cerebrovascular dementia,
Interrogation test execution device comprising an interrogation result input device (6) for inputting the results of each question of a dementia diagnosis interrogation test set in advance and an arithmetic unit (2) for totaling the number of scores corresponding to the results of each question Means (STP1 to 3);
Based on the image of the pupil imaging device (10) that images the pupil on the eye drop side with a constant illuminance when the Alzheimer diagnostic mydriatic diluent is applied to one eye, the size of the pupil is determined within a predetermined measurement time. In addition, the measured pupil size is normalized by the pupil size of the non-eyedrop side imaged at the same time, and the normalized pupil size change is displayed as mydriatic data. A dementia diagnosing apparatus having a mydriatic test execution means (STP6 to 15). Control device for executing processing by mydriatic test execution means (STP6-15) when the total score calculated by the inquiry test execution means (STP1-3) is near or above a preset cutoff point The dementia diagnosis apparatus according to claim 2, which is provided. The dementia diagnosis apparatus according to claim 2 , wherein the dementia diagnosis inquiry test is a Hasegawa scale or MMSE. The reference line indicating the cut-off point of the diagnostic test for dementia and the Alzheimer-type dementia using the score of the diagnostic test for dementia diagnosis and the point where the average or maximum value of the size of the pupil on the eye drop side is the XY coordinate The dementia diagnosis apparatus according to claim 2, further comprising a display device (7) for plotting on a graph on which a reference line indicating a size of a pupil serving as a determination reference is displayed. A device for diagnosing dementia that monitors the therapeutic effect of a therapeutic agent for Alzheimer-type dementia,
Based on the image of the pupil imaging device (10) that images the pupil on the eye drop side with a constant illuminance when the Alzheimer diagnostic mydriatic diluent is applied to one eye, the size of the pupil is determined within a predetermined measurement time. At a predetermined time interval, and the measured pupil size is normalized by the pupil size on the non-eye-dropped side simultaneously imaged, and the normalized pupil size change is stored as mydriatic data. Mydriatic test execution means (STP6-15),
A display device (7) for displaying the respective mydriatic data measured by the mydriatic test execution means by instilling a mydriatic diluted solution into the left and right pupils before and after administration of the Alzheimer-type dementia therapeutic agent; A dementia diagnosis apparatus comprising: An iris pattern is stored when the pupil image is captured by the pupil imaging device (10), and the iris pattern is collated with a pre-stored iris pattern each time a pupil image is input. The dementia diagnosis apparatus according to any one of claims 1 to 6, further comprising an identification unit (STP7).

Images